Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
53 hedge funds and large institutions have $20.1M invested in Clearside Biomedical in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 25 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.3% less ownership
Funds ownership: 1.81% → 1.52% (-0.3%)
12% less funds holding
Funds holding: 60 → 53 (-7)
18% less call options, than puts
Call options by funds: $305K | Put options by funds: $372K
46% less capital invested
Capital invested by funds: $37.4M → $20.1M (-$17.3M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
64% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$103K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$57.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.1K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$35.1K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$32.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.22M |
| 2 |
Morgan Stanley
New York
|
-$874K |
| 3 |
Two Sigma Advisers
New York
|
-$480K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$314K |
| 5 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$276K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Jane Street
New York
| – | -$197K | -5,748 | Closed |
|
|
XT
52
XTX Topco
George Town,
Cayman Islands
| – | -$117K | -3,396 | Closed |
|
53
Principal Financial Group
Des Moines,
Iowa
| – | -$104K | -3,025 | Closed |
|
|
NDSI
54
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
| – | -$62 | -1,802 | Closed |
|
|
B
55
Bailard
Foster City,
California
| – | -$59K | -1,707 | Closed |
|
|
TSS
56
Two Sigma Securities
New York
| – | -$50K | -1,443 | Closed |
|
|
CSS
57
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$44K | -1,280 | Closed |
|
|
BCM
58
Bayesian Capital Management
Brooklyn,
New York
| – | -$35K | -1,033 | Closed |
|
59
UBS Group
Zurich,
Switzerland
| – | -$4.88K | -201 | -87% |
|
|
CMBA
60
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$3K | -78 | Closed |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -25 | Closed |
|
|
IAMOG
62
Investors Asset Management of Georgia
Atlanta,
Georgia
| – | +$413 | +17 | New |
|
63
Wells Fargo
San Francisco,
California
| – | +$558 | +23 | +767% |
|
CLSD Hedge Fund Activity: Q2 2022 in Review
53 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2022, worth a combined $20.1M — down 46% from $37.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLSD and 4 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $103K. The largest seller was Millennium Management, cutting an estimated $1.22M.
- 53 institutional investors held Clearside Biomedical (CLSD) as of Q2 2022, down from 60 in Q1 2022.
- Funds reported $20.1M of Clearside Biomedical stock for Q2 2022, down 46% quarter-over-quarter.
- 4 funds opened new Clearside Biomedical positions in Q2 2022 and 10 closed out, a net change of -6 holders.
- The largest Clearside Biomedical buyer in Q2 2022 was Susquehanna International Group, an estimated $103K added.
- The largest Clearside Biomedical seller in Q2 2022 was Millennium Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2022.